CRISPR Therapeutics (NASDAQ:CRSP) Issues Quarterly Earnings Results

CRISPR Therapeutics (NASDAQ:CRSP) released its earnings results on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

CRISPR Therapeutics Trading Up 0.5 %

Shares of NASDAQ CRSP traded up $0.21 during midday trading on Tuesday, reaching $39.62. The company’s stock had a trading volume of 2,007,161 shares, compared to its average volume of 1,931,213. The stock has a 50 day simple moving average of $42.77 and a 200-day simple moving average of $46.53. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $91.10.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. HC Wainwright initiated coverage on shares of CRISPR Therapeutics in a report on Monday, February 3rd. They issued a “buy” rating and a $65.00 price objective on the stock. JMP Securities restated a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Barclays reduced their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $77.59.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the transaction, the chief executive officer now owns 181,540 shares of the company’s stock, valued at $10,002,854. The trade was a 7.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.10% of the stock is owned by insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.